Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
161 hedge funds and large institutions have $731M invested in Revance Therapeutics, Inc. in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 61 reducing their positions, and 16 closing their positions.
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
3% more funds holding
Funds holding: 156 → 161 (+5)
10% more call options, than puts
Call options by funds: $14.1M | Put options by funds: $12.8M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 61
28% less capital invested
Capital invested by funds: $1.02B → $731M (-$284M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$19.1M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$10.2M |
| 3 |
PA
Perceptive Advisors
New York
|
+$6.7M |
| 4 |
BlackRock
New York
|
+$6.12M |
| 5 |
Millennium Management
New York
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$30.1M |
| 2 |
Jennison Associates
New York
|
-$10.6M |
| 3 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$9.18M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$3.9M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.79M |
RVNC Hedge Fund Activity: Q2 2022 in Review
161 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2022, worth a combined $731M — down 28% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RVNC positions and 16 closed out — a net gain of 8 holders — while 48 added to existing stakes and 61 trimmed.
The largest buyer was Capital World Investors, adding an estimated $19.1M. The largest seller was Capital International Investors, exiting entirely with an estimated $30.1M sold.
- 161 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2022, up from 156 in Q1 2022.
- Funds reported $731M of Revance Therapeutics, Inc. stock for Q2 2022, down 28% quarter-over-quarter.
- 24 funds opened new Revance Therapeutics, Inc. positions in Q2 2022 and 16 closed out, a net change of +8 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2022 was Capital World Investors, an estimated $19.1M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2022 was Capital International Investors, an estimated $30.1M sold.
Based on aggregated 13F filings for Q2 2022.